South State CORP. cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 23,738 shares of the medical research company’s stock after selling 53 shares during the period. South State CORP.’s holdings in Amgen were worth $5,906,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of the company. Moody Lynn & Lieberson LLC increased its stake in shares of Amgen by 2.6% in the first quarter. Moody Lynn & Lieberson LLC now owns 1,565 shares of the medical research company’s stock worth $389,000 after purchasing an additional 40 shares during the period. Folger Nolan Fleming Douglas Capital Management Inc. increased its stake in Amgen by 0.8% during the first quarter. Folger Nolan Fleming Douglas Capital Management Inc. now owns 4,986 shares of the medical research company’s stock valued at $1,241,000 after acquiring an additional 40 shares during the period. Lederer & Associates Investment Counsel CA increased its stake in Amgen by 0.4% during the first quarter. Lederer & Associates Investment Counsel CA now owns 10,280 shares of the medical research company’s stock valued at $2,558,000 after acquiring an additional 41 shares during the period. Colonial Trust Advisors increased its stake in Amgen by 2.0% during the first quarter. Colonial Trust Advisors now owns 2,091 shares of the medical research company’s stock valued at $520,000 after acquiring an additional 41 shares during the period. Finally, First Mercantile Trust Co. increased its stake in Amgen by 2.9% during the fourth quarter. First Mercantile Trust Co. now owns 1,578 shares of the medical research company’s stock valued at $363,000 after acquiring an additional 44 shares during the period. Institutional investors and hedge funds own 75.31% of the company’s stock.
A number of equities research analysts have weighed in on the company. Atlantic Securities reaffirmed an “underweight” rating and set a $200.00 price objective on shares of Amgen in a report on Tuesday, May 4th. SVB Leerink lifted their price objective on Amgen from $230.00 to $238.00 and gave the company a “market perform” rating in a report on Monday. Credit Suisse Group decreased their price objective on Amgen from $265.00 to $259.00 and set an “outperform” rating on the stock in a report on Wednesday, April 28th. Royal Bank of Canada decreased their price objective on Amgen from $220.00 to $217.00 and set a “sector perform” rating on the stock in a report on Wednesday, April 28th. Finally, Robert W. Baird reaffirmed a “sell” rating on shares of Amgen in a report on Thursday, April 29th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $256.81.
NASDAQ:AMGN traded up $5.60 during trading hours on Thursday, hitting $245.12. 142,267 shares of the stock were exchanged, compared to its average volume of 2,709,228. The company’s 50 day moving average is $247.33. Amgen Inc. has a twelve month low of $210.28 and a twelve month high of $276.69. The company has a debt-to-equity ratio of 3.34, a current ratio of 1.66 and a quick ratio of 1.34. The firm has a market capitalization of $140.83 billion, a P/E ratio of 19.84, a P/E/G ratio of 1.73 and a beta of 0.72.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Monday, April 26th. The medical research company reported $3.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.05 by ($0.35). Amgen had a return on equity of 93.84% and a net margin of 28.16%. The firm had revenue of $5.90 billion for the quarter, compared to analyst estimates of $6.30 billion. During the same period in the prior year, the company posted $4.17 EPS. The firm’s quarterly revenue was down 4.2% compared to the same quarter last year. On average, research analysts anticipate that Amgen Inc. will post 16.35 earnings per share for the current fiscal year.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Featured Article: VIX – Volatility Index
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.